Rahul Gandhi responsible if Modi comes back to power, Congress harming opposition: Arvind Kejriwal

Agencies
May 10, 2019

New Delhi, May 10: Delhi chief minister Arvind Kejriwal on Friday accused Rahul Gandhi of harming the SP-BSP alliance in Uttar Pradesh, the Left in Kerala, the Trinamool Congress in West Bengal and the Aam Aadmi Party in the national capital, saying the Congress chief will be responsible if Narendra Modi comes back to power.

The AAP national convenor's attack, during a wide-ranging interview to PTI, comes two days ahead of elections in Delhi, which is witnessing a three-cornered contest as talks for an alliance between the Congress and the AAP did not fructify.

"Congress is harming SP-BSP alliance in UP, Left in Kerala, TMC in West Bengal, TDP in Andhra and AAP in Delhi..If Narendra Modi comes back to power, Rahul Gandhi will only be responsible," Kejriwal said.

"It is appearing as if the Congress is fighting the polls against opposition parties and not against the BJP. The Congress is acting as a spoilsport," he added.

The Delhi chief minister alleged that Prime Minister Narendra Modi had "totally failed" in delivering anything in any of the key sectors and that is why he has been resorting to "fake nationalism".

"Modi-ji's nationalism is fake. It dangerous for the country," Kejriwal said.

"He is using the armed forces to get votes as he does not have any work to show," he alleged.

The AAP national convenor, who along with Anna Hazare led a massive anti-graft agitation against UPA II between 2011 and 2013, said Manmohan Singh as prime minister was a thousand times better than Modi.

Kejriwal said the BJP is not going to retain power.

"Our only aim is to stop Modi and Shah from coming back to power. We will support anyone other than the duo," he added.

He said his party will perform well in the national capital.

"A month back, I thought it will be a fierce fight. But the situation changed dramatically in the last 10 days. I am witnessing a situation similar to the atmosphere when we got 67 seats in 2015. I will not be surprised if we get all seven seats," he said.

Kejriwal said the BJP is seeking vote in the name of Modi but the AAP is banking on its work in the fields of education, health and water supply and lower electricity tariff.

"Modi-ji cannot say I made schools, hospitals, brought down electricity tariff, ensured drinking water supply. He failed in every sector. He has not delivered anything," he alleged.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 13,2020

New Delhi, July 13: The number of active Covid-19 cases in India crossed the 3 lakh mark on Sunday even as fresh infections during the day surged to another new peak, crossing 29,000 for the first time. After staying over 500 for the past two days, the daily death toll came down slightly to 492.

While the focus has been on recoveries, the number of active Covid-19 cases in the country has been steadily rising. It hit the 1 lakh mark on June 4 and went past 2 lakh 23 days later. It has taken just 15 days more to reach 3 lakh.

India reported 29,271 new cases on Sunday, the fifth straight day of record rise in daily infections. With this, the country’s coronavirus caseload has risen to 8,79,060, two days after hitting the 8 lakh mark, as per data collated from state governments. Active cases stood at 3,02,466 while more than 5.53 lakh people were declared cured of the infection.

Covid-19 deaths in the country rose to 23,175 after 492 fatalities were added on Sunday, translating to a case fatality rate of 2.6%. The CFR has been steadily dropping with the surge in cases.
 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 8,2020

Idukki, Jun 8: Devikulam MLA S Rajendran from CPM along with supporters staged a protest by blocking the Munnar-Udumalpet interstate highway here on Monday, demanding that action to be taken to prevent wild elephants entering into human settlements and destroying properties.

The protest started at 9.30 am and demand was made that senior forest officials should give them assurance of putting an end to the problem.

A police team led by Munnar Deputy Superintendent of Police (SP) Ramesh Kumar was camping in the area.

Wild elephants from the nearby forest are frequently trespassing into Munnar and last night two elephants destroyed a vegetable shop in the town.

If it was a lone elephant that the locals nicknamed as Padayappa that used to enter the human settlement, now along with him a baby elephant is also coming to the town at night.

The locals have named the second elephant Ganeshan. Though there were instances of them destroying crops and eating from vegetable shops, till now the duo has not attacked humans.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.